{"title":"Photobiomodulation for Age-Related Macular Degeneration","authors":"Srinivas R. Sadda","doi":"10.1001/jamaophthalmol.2025.0077","DOIUrl":null,"url":null,"abstract":"This Viewpoint examines results from the LIGHTSIDE trials for photobiomodulation to treat age-related macular degeneration and raises questions regarding the trial protocols and the efficacy and safety of the therapy.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"46 1","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaophthalmol.2025.0077","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This Viewpoint examines results from the LIGHTSIDE trials for photobiomodulation to treat age-related macular degeneration and raises questions regarding the trial protocols and the efficacy and safety of the therapy.
期刊介绍：
JAMA Ophthalmology, with a rich history of continuous publication since 1869, stands as a distinguished international, peer-reviewed journal dedicated to ophthalmology and visual science. In 2019, the journal proudly commemorated 150 years of uninterrupted service to the field. As a member of the esteemed JAMA Network, a consortium renowned for its peer-reviewed general medical and specialty publications, JAMA Ophthalmology upholds the highest standards of excellence in disseminating cutting-edge research and insights. Join us in celebrating our legacy and advancing the frontiers of ophthalmology and visual science.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
